Turan, 237 patient favipiravir late treatment study: 79% lower hospitalization [p=0.001], 11% slower recovery [p=0.51], and 22% faster viral clearance [p=0.001] https://c19p.org/turan
copied to clipboard
The effect of favipiravir versus hydroxychloroquine on clinical and laboratory findings in COVID-19 in healthcare workers
et al., The Brazilian Journal of Infectious Diseases, doi:10.1016/j.bjid.2022.102328
Retrospective 237 low-risk healthcare workers in Turkey, 123 treated with favipiravir and 114 treated with HCQ, showing lower hospitalization and faster viral clearance with favipiravir, and similar improvement. This study is subject to substantial confounding by time because the patients in each group are from different time periods with an overall period of 10 months including the beginning of the pandemic, resulting in significant differences in variants encountered and SOC. Propensity for hospital admission may also have changed significantly.
|
risk of hospitalization, 79.4% lower, RR 0.21, p = 0.001, treatment 4 of 123 (3.3%), control 18 of 114 (15.8%), NNT 8.0.
|
|
recovery time, 11.0% higher, relative time 1.11, p = 0.51, treatment 123, control 114.
|
|
time to viral-, 21.6% lower, relative time 0.78, p < 0.001, treatment 123, control 114.
|
| Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates |
This study is excluded in meta
analysis:
substantial confounding by time likely due to separation of groups in different time periods over an extended period of time.
Turan et al., 2/1/2022, retrospective, Turkey, Europe, peer-reviewed, mean age 33.4, 10 authors, study period 11 March, 2020 - 1 January, 2021, this trial compares with another treatment - results may be better when compared to placebo.
Late treatment
is less effective
is less effective
Please send us corrections, updates, or comments. Vaccines and
treatments are both valuable and complementary. All practical, effective, and
safe means should be used. No treatment, vaccine, or intervention is 100%
available and effective for all current and future variants. Denying the
efficacy of any method increases mortality, morbidity, collateral damage, and
the risk of endemic status. We do not provide medical advice. Before taking
any medication, consult a qualified physician who can provide personalized
advice and details of risks and benefits based on your medical history and
situation. FLCCC and WCH
provide treatment protocols.